The pyrimidinones mhcpe, 2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidinone ethyl ester (mhcpe, 1), 2,3dimethyl-5-benzyloxy-6-carboxy-4-pyrimidinone ethyl ester (dbcpe, 2) and N-methyl-2,3-dimethyl-5hydroxy-6-carboxyamido-4-pyrimidinone (N-MeHOPY, 3), are synthesized and their structures determined by single crystal X-ray diffraction. The acid-base properties of 1 are studied by potentiometric and spectrophotometric methods, the pK a values being 1.14 and 6.35. DFT calculations were carried out to determine the most stable structure for each of the H 2 L + , HL and L − forms (HL = mhcpe) and assign the groups involved in the protonation-deprotonation processes. The mhcpe − ligand forms stable complexes with V IV O 2+ in the pH range 2 to 10, and potentiometry, EPR and UV-Vis techniques are used to identify and characterize the V IV O-mhcpe species formed. The results are consistent with the formation of V IV O,
Introduction
The presence of vanadium in biological systems, its possible physiological roles and its therapeutic effects regarding its insulin-enhancing action and anticancer activity have driven a considerable amount of research. Particular interest has been devoted to the study of the potential benefits of vanadium compounds as insulin oral substitutes for the treatment of diabetes. Namely the role of the ligand has been a matter of debate: coordinated ligands should be able to improve the absorption in the gastrointestinal tract while also facilitating the transport and uptake of vanadium by the cells, reducing the dose necessary for producing an equivalent effect when compared to a vanadium salt/inorganic source.
Research has focused on the development of new and more efficient insulin-enhancing compounds as well as on understanding the mechanism of their action. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The mechanisms by which vanadium compounds mediate antidiabetic effects in vivo are not well understood. It is known that vanadate is a very potent inhibitor of phosphatases and other phosphorylases, 11, [14] [15] [16] [17] [18] and the key events appear to involve interactions with protein tyrosine phosphatases and tyrosine kinases. 11, [18] [19] [20] Several vanadium complexes have been found to have higher insulin enhancing activities than inorganic oxovanadium(V) or oxovanadium(IV) salts, but probably this improved efficacy probably relates to the increased bioavailability of the metal ion when involved in a complex rather than to increased potency at the phosphatase enzyme active sites. [19] [20] [21] [22] [23] Among the several complexes exhibiting insulin enhancing properties, V IV O(maltolato) 2 (BMOV) and V IV O(ethylmaltolato) 2 (BEOV) have been extensively studied from the chemical and pharmacological points of view. 8, [21] [22] [23] [24] [25] [26] Complexes with 3hydroxy-4-pyrones (3,4-HP) have also been extensively studied. 19, [24] [25] [26] [27] [28] [29] Replacement of the O atom of the pyrone ring by a N or N-R group yields pyridinone derivatives, and both families of compounds maintain the (O − , O − ) binding set, forming quite stable complexes with many metal ions. 28, 30 Pyridinones have been proposed as oral therapeutic chelators for Fe III and Al III removal, 31, 32 and the compound 1,2-dimethyl-3-hydroxy-4-pyridinone (Hdhp -Scheme 1), commercially known as Deferi-prone®, is used in the treatment of β-thalassaemia. [31] [32] [33] The complexation of V IV O 2+ and V V O 2 + with dhp was studied in aqueous solution [34] [35] [36] [37] [38] and exhibited quite interesting insulin like properties. 12, 13, 39, 40 Aiming at developing ligands with similar structural and binding ability characteristics of pyridinone and pyrone heterocycles, with improved aqueous solubility, we developed a distinct heterocyclic ligand system of the pyrimidinone type: 2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidinone ethyl ester, or mhcpe -Scheme 1containing two N atoms in the ring. 41 Pyrimidines, by virtue of substituting an additional carbon atom for a nitrogen atom in the heterocycle ring, reduce the capacity to tolerate the positive charge resulting from protonation and therefore may possess a more acidic protonation. However, depending on the nature and position of the substituting atoms of the ring, and the possibility of formation of intramolecular H-bonds, the actual protonation constants may be more or less basic than those of the corresponding pyridine compounds.
The system V V -mhcpe was previously studied by pH-potentiometry and 51 V NMR by some of us, and its cytotoxic activity was screened with two different cell lines (HeLa tumor cells and 3T3-L1 fibroblasts). 42 The toxic effects were found to be incubation time and concentration dependent. According to the IC 50 values and the results on reversibility to drug effects, the V V -mhcpe system showed higher toxicity in the tumor cells than in non-tumor cells, which may indicate potential antitumor activity. In this work we report the synthesis and characterization of mhcpe, and the study of its interaction with V IV O 2+ in aqueous anaerobic solution, using potentiometric and spectroscopic techniques.
It has been proposed that in higher organisms the delivery of vanadium into cells can be promoted by natural carriers such as plasma proteins, particularly by the high molecular mass (hmm) blood serum components: human serum transferrin (hTF) and human serum albumin (HSA). 22, 23, 40, [43] [44] [45] [46] [47] [48] [49] [50] Transferrin (hTF) is a single-chain glycoprotein containing around 630 amino acids which are arranged in two similar lobes, and is important for iron transportation. It is present in human blood plasma in about 37 μM concentration. It has two binding sites per protein to accommodate Fe III , one in each lobe, which is coordinated by two tyrosines, a histidine, an aspartate and a carbonate anion (the so-called synergistic anion) in a distorted octahedral geometry. 51 The binding mode of the metal ions at the two sites depends on the nature of the metal ion, the synergistic anion and the pH, but binding is generally slightly preferred at the C-terminal than at the N-terminal. 51 In normal serum, only about 30% of the total binding sites are occupied by iron. 7 This means that there are still sites available for other metal ions (corresponding to ca. 50 μM), without needing to replace the tightly bound Fe III . In fact hTF can bind strongly to a range of other metal ions, as is the case of V IV O 2+ . 23, 43, [48] [49] [50] Human serum albumin (HSA) is a globular protein consisting of a single polypeptide chain of 585 amino acids. It is the most abundant protein in plasma, accounting for ∼60% of total plasma protein, with a concentration of ca. 0.63 mM, being the most important nonspecific transporter protein in the circulatory system. 52 Since both albumin and transferrin play important roles in the distribution and transport of different compounds, they must be taken into account when evaluating the interactions and/or speciation of any metal-containing drugs once in human blood. Besides hTF and HSA other constituents should also be considered in any model which attempt to elucidate the fate of vanadium in human blood plasma. Strong evidence has been provided to support that most of the vanadium in the serum is bound to hTF, even in the absence of HCO 3 − . 22, 23, 40, 43, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] The results indicate that two vanadium ions are bound to the metal-ion-free apo-hTF, at the usual specific Fe III binding sites. Under the physiological conditions, particularly in the hypothetical situation where the vanadium concentration is higher than ca. 50 μM, albumin may also participate in vanadium binding. If vanadium is introduced in blood in the form of a V IV O(carrier) 2 complex (carrier = bidentate ligand), these carrier ligands and/or low molecular mass (lmm) bioligands may also participate in the transport of vanadium in blood. 23, 40, 43, [45] [46] [47] [48] [49] [50] In this work we also report and discuss our findings by CD, EPR, and 51 V NMR spectroscopy regarding the interaction of V Vand V IV -mhcpe and vanadium-mhcpe complexes with human serum apo-transferrin (apo-hTF), as well as CD studies of interaction of V IV -dhp and V IV -maltol with apo-hTF and HSA in concentrations corresponding to those present in blood serum.
Results and discussion

Synthesis and characterization
The pyrimidinone mhcpe 1, depicted in Scheme 1, was prepared as outlined in Scheme S-9-1 † (see also the Experimental section), while dbcpe (2) was synthesized from one of the intermediates and N-MeHOPY (3) was obtained from 2, as indicated in Scheme S-9-1. † 41 These compounds were characterized by 1 H and 13 C NMR, mass spectrometry and by single crystal X-ray diffraction, and their purity was confirmed by elemental analysis.
Crystals of 1 (mhcpe), 2 (dbcpe) and 3 (N-Me-HOPY), suitable for X-ray diffraction studies, were obtained. Ortep diagrams with the molecular structures are depicted in Fig. 1 . In the crystals of mhcpe the N(1) atom is protonated and N(2) is not protonated. Atoms O(2)-H⋯O (3) 
In the crystal packing of mhcpe an offset-face-toface (OFF) interaction is observed with a distance between the centres of both rings of 4.442 Å ( Table 1) . 58 The solid state structure of dbcpe (2) has no hydrogen bond interactions. In the crystal of N-MeHOPY the hydrogen bond interactions differ from those of 1. Aromatic-aromatic intermolecular interactions are present in the crystal packing of the crystals of mhcpe and of N-MeHOPY (see the ESI † section), and a comparative view of the π-π-stacking and hydrogen bonding interactions in the crystal packings of 1 (mhcpe) and
Solution studies
Ethyl 5-hydroxy-2-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylatemhcpe. The protonation equilibria were studied in the pH range of ca. 0.5 to 12 by UV absorption spectroscopy and in the pH range of ca. 1.8 to 12 by pH-potentiometry, at an ionic strength of 0.20 M KCl. Individual calibration curves of EMF vs. [H + ] were established for pH values <∼2, valid for the present medium and electrodes. For this purpose a set of HCl solutions were prepared with known H + concentrations, all with an ionic strength of 0.20 M. This calibration curve was used for all measurements below ca. pH 2.
Only two protonation steps were observed. Fig. 2 depicts several of the UV absorption spectra obtained. The protonation constants of the ligand were calculated with the PSEQUAD computer program 59 using both the experimental UV spectra and potentiometric titrations, and the results are included in Table 2 . The calculated pK a values from the UV spectra are: pK a1 = 1.14 and pK a2 = 6.34. The pK a2 calculated from the pHmetric titrations is 6.36.
1 H NMR titration studies carried out in the pH range 1-8 made with solutions containing mhcpe led to inconclusive results as to where the protonation-deprotonations took place as the protons on the mhcpe molecule did not afford relevant information in this regard. To better understand the protonation and deprotonation processes, a thorough conformational study was carried out for H 2 L + , HL and L − by means of DFT calculations. 60 The stability of the several tautomers (18) considered may depend, to some extent, on solvation and ionic interactions occurring in solution. Since the solvent is water, solvation will rely on H-bonds established between the solute and solvent; as the comparison is made between isomers, part of the solvation effects are expected to cancel, and the energy differences calculated with implicit solvent corrections (PCM model, see the DFT computational details section) should give important clues to understand the predominant species in aqueous solution, in each case. The structures of several tautomeric forms were calculated in a thorough search for each stoichiometry H 2 L + (a total of 8 tautomers), HL (a total of 10 tautomers) and L − (a total of 5 tautomers). The structures presented in Scheme 2 and discussed above correspond to the most stable tautomers, with energy differences less than 10 kcal mol −1 (see the section ESI-1 †) with respect to the most stable tautomer of each stoichiometry. Additional metric and electronic parameters for the optimized structures are provided in the ESI † section, as well as the atomic coordinates for all optimized species. Partial charges and Wiberg indexes are also given in the section ESI-1. † For 3-hydroxy-4-pyridinone derivatives there is some consensus in the literature that the protonation of the HL species takes place mainly on the N atom of the ring and the pK a1 values obtained, in the range 3.5-3.8, are several orders of magnitude higher than those for 3-hydroxy-4-pyrones. 28, 35 This may be explained considering that in the H 2 L + form of the compounds, the N atom is more efficient in delocalizing the positive charge in the ring than the O atom. Accordingly, for the H 2 L + form of the pyrimidinone mhcpe the most stable form (DFT-2 in Scheme 3) corresponds to the tautomeric form where both N-atoms are protonated. The tautomeric form a The values given as (±x) for the vanadium complexes are not the standard deviations obtained directly by the PSEQUAD program; the values given account for the range in the log β values obtained in the several equilibrium models tested using the potentiometric and spectrophotometric data. These values are thus higher than the SDs given by the individual calculations of PSEQUAD.
Scheme 2
The most stable structures calculated for H 2 L + (top), HL (center), and L − (bottom). Solvent (water) effects were considered in the energy calculations. The stability difference between tautomers (kcal mol −1 ) is indicated for each stoichiometry, the structures depicted on the left side being the most stable ones for each protonation state.
where N(2) is protonated and N(1) is deprotonated (DFT-1) is less stable by 5.6 kcal mol −1 , and the form where atom N(2) is deprotonated and atom N(1) is protonated (DFT-3) is less favorable by +9.7 kcal mol −1 . The pK a2 values obtained for pyridinones, in the range 9.7-9.9, 28, 35 show that pyridinones are stronger bases than pyrones. This has been attributed to the delocalization of the partial negative charge to the O atom in position 4 of the ring. 28, 35 For the HL species of mhcpe the most stable tautomer corresponds to the one characterized by X-ray diffraction. The tautomer with N(1) deprotonated and atom N(2) protonated is less stable by 4.6 kcal mol −1 (DFT-6), and the tautomer with both N atoms deprotonated is less favourable by 8.4 kcal mol −1 (DFT-5).
For the L − species, the most stable tautomer corresponds to DFT-9, where the O-atoms that may coordinate to metal ions are not protonated. The other two tautomers present similar stabilities: in DFT-8 (+4.2 kcal mol −1 ) the negative charge is delocalized over the ring and atom O(1), and in DFT-7 (+5. 
V IV O-mhcpe complexes
Structure and binding constants. The mhcpe ligand binds V IV O 2+ reasonably well at low pH. Fig. 3 includes visible spectra (Vis spectra) of solutions containing V IV O 2+ and mhcpe with a ligand-to-metal molar ratio (L : M ratio) of 2.76. At low pH values, e.g. ∼1.0, the UV-Vis spectra already differ from the spectrum of the free V IV O 2+ ion (in fact: [V IV O(OH) 5 ] 2+ ), namely in the 600-900 nm range, clearly indicating extensive complex formation at this pH. Band II (d xy → d x 2 −y 2) and charge-transfer bands progressively build up at ∼480 nm, bathochromic effects being observed with an increase in pH, and band I (d xy → d xz ,d yz ) 61 also increases its intensity and also shows a red shift up to pH = 6.68, as highlighted by the arrows in Fig. 3 .
Fig. S-2-1 † includes representative Vis spectra for pH > 6.6. Globally the Vis spectra change significantly as the pH is increased particularly for pH > ca. 7, but do not change much in the pH range ca. 4.5-6.5. Moreover, while up to pH 7.2 the Vis spectra do not change much with changes in the L : M ratio [varying the C VO from 2 to 6 mM keeping C mhcpe approximately constant] indicating that no oligomeric species form, for pH > 7.5 similar types of experiments show changes indicating the formation of oligomeric species, and hydrolysis for pH > 8-9. The extension of the hydrolytic processes depends on the L : M ratio used.
The complex formation constants were calculated with the PSEQUAD computer program 59 from the potentiometric titration data at different C VO , C mhcpe and L : M ratios (see the Experimental section). The best model refined from experimental data includes stoichiometries (oxidation state and charges omitted for clarity): VO, (VO)L, (VO)L 2 , (VO) 2 L 2 H −2 , (VO)L 2 H −1 , (VO) 2 L 2 H −3 and (VO)LH −2 . The log β of a few other stoichiometries could be obtained in some calculations, but either they were obtained with high standard deviations (SD) and/or they were not obtained with consistent values and/or they did not improve the fitting parameter, and were thus ruled out.
The PSEQUAD computer program and the Vis spectra obtained under different conditions (C VO , C mhcpe , L : M ratios and pH values) were also used to calculate the log β and/or the spectrum of each individual species formed. The calculated log β values calculated from spectral data agree well with those obtained from the pH-potentiometry (within ±0.1 log unit), and Vis spectra (included in the ESI † section) in agreement with the experimental data recorded could be calculated for almost all species included in the equilibrium model; this confirms that the speciation model proposed and the log β values calculated are correct and reliable. These data are included in Table 2 and a concentration distribution diagram is presented in Fig. 4 .
It is clear from the speciation diagram that the mhcpe ligand forms quite stable complexes with V IV O 2+ in a wide pH range, its hydrolytic products only forming in measurable concentration for pH > 7.5. At pH ∼ 7 V IV O 2+ is chelated in solution by mhcpe as Plausible binding modes. EPR spectra were measured in "frozen" solution (77 K) to confirm the speciation model and to elucidate binding modes for each species. Some of the EPR spectra obtained for the V IV O-mhcpe system, in the range corresponding to M I = 5/2 and 7/2 (in the high field region of the spectrum), are depicted in Fig. 5 . Table 3 summarises spin Hamiltonian parameters obtained in the V IV O-mhcpe system from the simulation of the EPR spectra. 63 Four main species, designated as I-IV and assigned to stoichiometries (VO)L, (VO)L 2 , (VO)L 2 H −1 and (VO)LH −2 , can be identified as the pH is increased from 2 to 11 ( Fig. 5 , Table 3 ). The EPR spectral intensity decreases slightly in the pH range 4-6, and remarkably for pH > 7, in agreement with the formation of two dinuclear species: (VO) 2 L 2 H −2 ( present in very low concentration) and (VO) 2 L 2 H −3 , the latter probably being responsible for the broad weak feature detected at pH ca. 7.5 (at its maximum concentration) identified as IIIA in Fig In Scheme 3 we depict the most plausible binding modes for the present V IV O-mhcpe system, and in the ESI † section we present a detailed discussion, based on the EPR data and additivity rule, of how we estimated A z O− values for the mhcpe ligand as well as a discussion on how these binding sets were established. Table 3 . Comparison of the binding ability of V IV O 2+ to mhcpe, dhp and maltol
Considering the formation constants included in Table 2 for V IV O-mhcpe complexes, and those for V IV O-dhp 35 and V IV Omaltol, 68 and taking into account the hydrolytic V IV O-species and protonation constants of the ligands, the −log[V IV O 2+ ] (= pVO) may be obtained, thus giving a measure of the binding ability of these ligands towards V IV O 2+ . The values calculated are plotted in Fig. 6 . It may be seen that mhcpe and maltol have a quite similar binding ability towards V IV O 2+ in the pH range 2-10, while that of dhp is significantly higher, particularly for 3 < pH < 6.
Considering the role of the ligand as a carrier for the metal ion (improving its absorption and transport to the target tissues/cells) an adequate binding ability is critical: the ligand is expected to bind V IV O 2+ (in this case) efficiently enough to prevent hydrolysis and other side-reactions while allowing its release when appropriate. In this context, maltol being a proven effective carrier ligand for V IV O 2+ , and mhcpe exhibiting a similar adequate binding ability, we also expect this ligand to release the metal ion in the presence of adequate competitive bioligands.
Ternary systems V IV O-amino acid-mhcpe
Following administration (either oral or by intravenous injection), any pharmaceutical will eventually be transported and distributed within the living system by the blood. If a vanadium complex, e.g. of V IV O(carrier) 2 type, as is the case of V IV O(mhcpe) 2 , is taken orally or injected, during its transport in the blood stream complex formation with the serum components must be considered, namely with (i) some of the lmm constituents (the most potent binders are probably the negatively charged O donor-containing ligands), such as lactate, phosphate, oxalate and citrate, designated here as ligands B, and with (ii) the hmm protein constituents, e.g. human serum albumin, immunoglobulin G and transferrin. In this work we mainly address the binding of vanadium-mhcpe to hTF.
As mentioned above, in iron bound hTF each lobe contains a distorted octahedral Fe III binding site consisting of two Tyr, one His, one Asp residues, and one bidentate carbonate anion, the two binding sites being similar. To test the formation of ternary (and quaternary) V IV O-complex species in solution, namely including the mhcpe ligand, some model systems (L-His, L-Tyr, L-Asp, Gly-L-His, Gly-L-Asp, L-Asp) were evaluated at pH ca. 7.2 by measuring their CD spectra in solution. Most of these results are included in the ESI-3 † section.
The degree of complex formation in solutions only containing V IV O 2+ and amino acids in the pH range 6-8 with L : M ratios up to 4 is usually low, V IV O-hydrolytic products normally predominate and often V IV O(OH) 2 precipitates. 61, 62 Adding mhcpe to these solutions the degree of formation of V IV Ohydrolytic species decreases significantly and ternary species typically form, probably V IV O-mhcpe-amino acidato complexes. In fact, if mhcpe is added to solutions containing V IV O 2+ and several amino acids, e.g. L-His and L-Asp, the CD signal in the visible range increases significantly and the pattern of the CD spectra differs from those observed for the V IV O(amino acidato) or V IV O(amino acidato) 2 complexes. 61, 62, [69] [70] [71] [72] [73] [74] [75] In Fig. 7 we present one such example: the intensity of the CD signal corresponding to spectrum c (V IV O : mhcpe : L-His at 1 : 1 : 3 ratio) is much higher than in the absence of mhcpe, where V IV O 2+ is extensively hydrolysed. Upon addition of L-Asp to the solution of spectrum c, the CD signal changes, yielding spectrum d, suggesting the formation of distinct optically active complexes. In section ESI-3 † several similar experiments are also described. Globally these indicate that ternary V IV O-mhcpe-LIG complexes significantly form when LIG is L-His or L-Asp, but not when LIG corresponds to L-Tyr, Gly-L-Asp, lactate or citrate. Interaction of vanadium-mhcpe complexes with apotransferrin CD spectroscopy is frequently used to monitor protein-drug interactions by following changes in the protein spectrum in the wavelength range 190-350 nm. In particular, the protein spectrum in the 200-250 nm range yields information on its secondary structure and on the changes it undergoes upon the binding of a compound, while the CD signal in the range 250-350 nm can be traced to the contribution from aromatic residues (Phe, Tyr, Trp) of the protein. Above 350 nm the protein is CD silent. However, in the case of the interaction of metal complexes, an induced CD signal (ICD)resulting from chirality that is transmitted to metal-related electronic transitionscan be observed only if it binds in close proximity to chiral groups (this is what is observed in Fig. 9 ). The development of an ICD signal yields clear evidence of a strong interaction between the protein and the complex. Upon the stepwise addition of mhcpe up to a mhcpe : hTF molar ratio of 10 : 1, C hTF ≈ 100 μM, in either Hepes-S or Hepes-CL buffer (CL buffer: similar to Hepes-S but also containing citrate and lactate, see the Experimental section), no significant changes are seen in the CD spectra in the 250-400 nm range (see Fig. S -5-1 and -2 †). This means that mhcpe does not interact strongly with hTF under these experimental conditions. In contrast, if a 1 : 1 or 1 : 2 V IV O : mhcpe solution is progressively added to apo-hTF, the CD spectra show important changes (see Fig. 8 ), particularly in the wavelength range 310-360 nm where the protein alone shows no CD signal.
Dalton Transactions Paper
The induced CD band at ca. 300-360 nm (centered at ∼330 nm), clearly observed in Fig. 8 , could be due to mhcpe absorption (see Fig. 2 ), and indicates that the mhcpe ligand is interacting closely with hTF; otherwise no CD band would be visible in this wavelength range. As this band is only observed when V IV O 2+ and mhcpe are both present, this implies that mhcpe is also bound to V IV O. Additional proof of this binding is given below. Similar measurements made in Hepes-S buffer (section ESI-6 †) show very similar CD spectra, but the Δε values in the 320-360 nm range are ca. 25% higher, possibly because the citrate and lactate present in the Hepes-CL buffer partly sequester the V IV O 2+ , decreasing the amount bound to hTF. It is interesting to note that quite similar CD spectra, giving equivalent information, were obtained with solutions containing (i) V IV OSO 4 , maltol and apo-Tf and (ii) V IV OSO 4 , dhp and apo-hTF (section ESI-6 †), thus also confirming the formation of ternary V IV O-maltol-hTF and V IV O-dhp-hTF complexes. 57 Fig. 9 presents CD spectra (recorded with a 50 mm optical path quartz cell, see the section ESI-4 †) in the 400-1000 nm range (designated here as the Vis range) of solutions containing apo-hTF and either (A) one equiv. or (B) two equiv. of V IV OSO 4 , and progressively adding mhcpe. All bands observed for λ > 500 nm correspond to d-d transitions of the V IV center of the V IV O unit. In this wavelength range CD signals can only be observed if the V IV O-species present are in close-interaction with chiral protein groups. Different CD signals must correspond to different types of V-species present and interacting with chiral protein groups. 61, 62, [69] [70] [71] [72] [73] Fig. 9 clearly shows that the V IV O-protein CD spectra totally change upon adding mhcpe (spectra c-f ), and therefore different V IV O-species are formed. Namely, the pattern of the CD spectra corresponding to (V IV O) 1 (hTF) and (V IV O) 2 (hTF) complexes, due to one or two V IV O-centres bound to apo-hTF in the iron binding sites, is no longer observed, thus implying that the mhcpe ligand binds to the V IV O centres which probably remain bound in the iron binding sites. The addition of up to 1.0 equiv. of mhcpe (relative to the V IV O present) causes a total change in the pattern of the ICD bands, namely the d-d bands Ib and Ia change signal, and band II becomes more negative, 61 but further additions of mhcpe do not change much the ICD bands measured. Quite similar CD spectra and trends were found when adding solutions containing either V IV OSO 4 and mhcpe in 1 : 1 or 1 : 2 molar ratios to solutions containing apo-hTF at pH 7.4 (see the section ESI-7 †). All observations suggest the formation of complexes with stoichiometries (V IV O) 1 (hTF)(mhcpe) 1 , (V IV O) 2 (hTF)(mhcpe) 1 and (V IV O) 2 (hTF)(mhcpe) 2 . Fig. 10 depicts several EPR spectra of frozen solutions containing apo-hTF and V IV OSO 4 , and of solutions containing apo-hTF, V IV OSO 4 and mhcpe. The EPR spectra differ when the mhcpe ligand is present, as was observed with the CD spectra (above), clearly indicating that a modification of the V IV Obinding set changes when mhcpe is added to solutions containing apo-hTF and V IV OSO 4 . The number of distinct species detected and spin-Hamiltonian parameters do change, but as most donor groups give rather similar contributions to the g z and A z values, the modifications observed on the spectral lines are not drastic. Moreover, in the case where mhcpe is present we can observe the presence of the two new environments that we have labelled C and D, characterized by distinct A z values ( Table 5 ). The environment corresponding to C appears to be preferred over D. This behaviour was observed in both buffers, Hepes-S and Hepes-CL (the g and A values in both are equal), but the formation of D is slightly enhanced when the Hepes-CL buffer is used.
Calculation of conditional stability constants. The stability constants of the (V IV O)-hTF and (V IV O) 2 -hTF species were determined 40 from the CD spectra and the isotropic/anisotropic EPR signal ratios with the computer program PSEQUAD 59 as: log K 1 = log β 1 = 13.4 and log K 2 = 11.9 (log β 2 = 25.3), respectively; these are conditional stability constants only valid at pH 7.4. Sanna et al. 76 obtained similar log β 1 and log β 2 values.
The stability constants of the ternary species (V IV O) p (hTF) 1 (mhcpe) r were determined from the experimental CD spectra with different V IV O-hTF-mhcpe molar ratios, also using the computer program PSEQUAD. The protonation constants of the ligands, the stability constants of the V IV Omhcpe complexes, and the hydrolytic constants of V IV O were all taken into account as fixed parameters in the calculations. The conditional stability constants for the binary species (V IV O)-hTF and (V IV O) 2 -hTF were also considered with the known values. The stability constants calculated are presented in Table 4 , and a speciation profile is depicted in Fig. 11 for an hTf concentration close to that of the human plasma. The corresponding CD spectra were also calculated and are shown in Several questions remain open, e.g. whether ternary or quaternary V IV O-complexes form, which hTF donor groups/residues bind to the metal centre and if hTF can assume (or not) the closed conformation recognizable by the transferrin receptor in the presence of mhcpe ( probably yes). 57 Interaction of vanadium-mhcpe complexes with transferrin in the presence of iron As mentioned above, in normal serum, only about 30% of the total Fe III binding sites are occupied by this metal ion. As the hTF concentration in blood serum is ca. 37 μM this means that there are sites available for binding other metal ions, corresponding to ca. 50 μM, with no need to replace the tightly bound Fe III . Therefore, hTF can also bind strongly to a range of other metal ions, as is indeed the case of V IV O 2+ .
In solutions containing V IV O 2+ and hTF under conditions where there are enough free available sites for the binding of all V IV O 2+ present, we observed that this metal ion is more easily oxidized to V V than in the absence of Fe III . This is an interesting observation considering that V IV binds to hTF much more strongly to hTF than V V . 40, 47 A similar effect was observed in solutions also containing mhcpe, maltol or dhp. In Fig. 12 spectrum 1 corresponds to the EPR spectrum of a frozen solution containing apo-hTF (C hTF = 0.75 mM), V IV OSO 4 (C VO = 1.50 mM) and Fe III (C Fe = 0.45 mM) at pH 7.4; the presence of both the V IV O-hTF and Fe III -hTF EPR signals is clearly seen. An EPR spectrum very similar to this one was recorded with a solution containing apo-hTF and V IV OSO 4 (1 : 2 molar ratio), and upon addition of Fe III to this solution. The Fe III added removed an equivalent amount of V IV O 2+ from the hTF Fe-binding sites and the intensity of the V IV O-EPR spectrum decreased accordingly. The excess V IV O removed by the addition of Fe III or that present in the bulk solution of spectrum 1 of Fig. 12 is not detected as it is in the form of EPR silent species and/or was oxidized to vanadate species. 61, 62 Upon addition of mhcpe the V IV O-EPR spectrum changes due to the formation of V IV O-hTF-mhcpe complexes. As mentioned above, in the presence of Fe III the ICD spectra in the visible range decrease rather fast and the intensity of the V IV O-EPR progressively decreases accordingly. The Fe III -EPR spectra show some changes probably due to the formation of Fe III -mhcpe complexes. Table 5 . Table 4 Conditional formation constants a determined for the ternary [(V IV O) p (hTF) q (mhcpe) r ] system ( p, r = 0-2; q = 1) using CD data and the computer program PSEQUAD 59 The 51 V NMR spectrum of the solution of spectrum 3 of Fig. 12 was also measured and two resonances were observed: the signal corresponding to V V -hTF species (at δ = −532 ppm) and a low intensity signal corresponding to V V -mhcpe complexes 42 (at δ ≈ −538 ppm). This means that upon addition of Fe III to the solution containing apo-hTF and V IV O 2+ , in a 1 : 2 molar ratio, the V IV O 2+ is oxidized to some extent to V V -species which in turn bind to hTF. In the ESI † section additional information regarding EPR and 51 V NMR spectra measured is included.
Upon addition of Fe III to solutions containing apo-hTF and V IV OSO 4 (1 : 2)spectrum 1 of Fig. 13 Fig. 13 it can also be concluded that the spin-Hamiltonian parameters of the species present are slightly different, suggesting the presence of new species, designated by C and D, distinct from those detected in solutions of V IV O 2+ and mhcpe at pH ≈ 7.4 (e.g. spectrum 7). No 51 V NMR signal corresponding to any hTF-V V -mhcpe species was detected in this or in other experiments.
In Table 5 the spin Hamiltonian parameters obtained for the species formed in the V IV O-apo-hTF-mhcpe-Fe system are summarized. The EPR signal corresponding to the V IV Ospecies E differs significantly from those labelled as C or D, but corresponds to parameters very similar to those of A (or B), assigned to (V IV O)-hTF species. However, it is not likely that they indeed correspond to (V IV O) n -hTF complexes as the CD spectrum measured differs from those of (V IV O) n -hTF complexes. We believe that this corresponds to a distinct complex, not previously detected; a possible assignment is the formation of a V IV O-hTF bound species involving vanadate as a synergistic anion.
The reason why in the presence of Fe III the spectroscopic CD and EPR signals of V IV O present disappear relatively fast (much faster than in its absence) is not clear. A plausible explanation is that in the presence of Fe III some of the V IV O is removed from the stronger hTF binding sites, which increases the relative amount of V IV O not bound to the protein. As the pH of the solution is 7.4, this non-hTF-bound V IV O may be easily oxidized even if the amount of O 2 present is very low. If the amount of O 2 increases, e.g. by removing the stoppers of the cell, the oxidation proceeds much faster. Addition of glutathione to the solution does not promote the reduction of the V V -species formed back to V IV (see the ESI-8 † section). This relatively fast oxidation in the presence of O 2 occurs even if there is enough hTF to bind all V IV O and all Fe III present.
The implications of these observations for in vivo conditions cannot be anticipated easily. There are no reports stating that the oxidation of V IV O may proceed in blood. In contrast, it is usually assumed that V IV O-species are stabilized and protected from oxidation by the presence of several biological reducing agents. 61, 79 A possible explanation is that vanadate may act as a synergistic anion for Fe III (and possibly also for V IV O) binding to hTF, this being a driving force for the Fig. 12 (with the same numbering) . The spin Hamiltonian parameters obtained by simulation of these EPR spectra are summarized in Table 5 . partial oxidation of V IV O. Further studies are being carried out to understand the processes taking place in these systems. 2 solution, the pattern of the CD spectra does not change, but the |Δε| values globally increase. As mhcpe and V IV O-mhcpe complexes absorb in this wavelength range, ICD bands may be responsible for the increase in the Δε values. Thus, we cannot conclude with certainty that upon addition of a complex there are conformational changes of the protein; probably these changes take place but are not very extensive.
Interaction of vanadium-mhcpe complexes with human serum albumin
Interactions of vanadium-mhcpe complexes with hTF and HSA with concentrations close to those expected in blood plasma
In the UV region, namely in the 290-390 nm range, HSA has a negative band up to ca. 330 nm, and the Δε values are ca. zero for λ > 330 nm. Fig. 15 depicts the changes observed upon adding a solution containing V IV OSO 4 and mhcpe (1 : 2 molar ratio) trying to simulate in vivo conditions, where it is likely that the concentration of V IV O or V IV O-complexes will not be higher than 80 μM ( possibly it will be lower, except for short periods if V IV O-complexes are introduced by injection). The changes observed are significant, i.e. V IV O-mhcpe complexes bind to HSA and this yields very small changes in the CD spectra in this wavelength range, namely at ca. 320-350 nm where mhcpe presents a relatively strong band (see Fig. 2 ). Fig. 16A depicts CD spectra of solutions containing HSA and hTF in concentrations close to those present in human blood plasma. Spectrum (a) corresponds to the CD signal for the solution containing the two proteins, and (b-e) after stepwise additions of a solution containing V IV OSO 4 and mhcpe in a 1 : 1 molar ratio. The spectra of Fig. 15 and 16A differ significantly and clearly indicate that hTF is the main V IV O-binder, ternary (at least) hTF-V IV O-mhcpe species being formed. In fact, comparing what is depicted in Fig. 15, 16A and 16B , the changes observed in Fig. 16A are indeed very similar to those observed in solutions only containing hTF and V IV OSO 4 , namely the clear observation of the strong ICD band of mhcpe with λ max at ca. 330 nm. Quite similar observations were made with solutions containing HSA (0.630 mM) and hTF (40 μM) and adding V IV O(dhp) 2 or V IV O(maltol) 2 (see the section ESI-6 †). For these simulated human blood plasma conditions, hTF is again the main V IV O-binder, with ternary (at least) hTF-V IV O-dhp or -maltol species also being formed.
Clearly, as in the case of the solutions containing amino acids or dipeptides (see above), the formation of ternary species HSA-V IV O-mhcpe enhances the interaction of the metal ion with chiral groups of the protein, the intensity of the ICD bands due to V IV d-d transitions increasing. Sanna 
Transport of vanadium-mhcpe complexes in blood
If the compound is taken orally, a significant amount of V IV Omhcpe complexes may be present at the pH of the stomach, as inferred from the obtained speciation diagram (Fig. 4 ), but presently it is not possible to anticipate if the V IV O-mhcpe complexes will be extensively absorbed in the gastro-intestinal tract or not. The models described indicate that when V IV O-mhcpe complexes are introduced into the blood stream, the V IV O moiety will preferentially bind to hTF forming hTF-V IV O-mhcpe complexes. However, thermodynamic models correspond to equilibrium conditions and these cannot be unambiguously applied to living systems. If only thermodynamic considerations are assumed, it may be anticipated that if a small amount of a solution containing V IV O-mhcpe complexes is injected into blood, the metal ion is transported by hTF mainly as (V IV O) (hTF)(mhcpe) and (V IV O) 2 (hTF)(mhcpe) 2 complexes.
Conclusions
A new pyrimidinone, mhcpe (HL), was synthesized, its structure determined by single crystal X-ray diffraction and its acid-base properties were studied by potentiometric and spectrophotometric methods, as well as by DFT calculations. The most stable structure for each of the H 2 L + , HL and L − forms in aqueous solution was established, thus enabling the assignment of the groups involved in the protonation/deprotonation processes: a proton bound to a N-ring atom in the case of K a1 and an O-catecholate-type proton in the case of K a2 .
Aqueous solution studies regarding the identification and characterization of complexes formed by V IV O 2+ and mhcpe were carried out in the pH range 2-11 using potentiometry, EPR and UV-Vis techniques. An equilibrium model was established as well as the binding modes corresponding to each stoichiometry. The mhcpe − ligand forms quite stable complexes with V IV O 2+ , the global binding ability being similar to that of maltol − and lower than that of dhp − . The possibility of formation of ternary complexes V IV O-mhcpe-L′ with several amino acids was confirmed.
The interaction of V-mhcpe complexes with human plasma proteins (transferrin and albumin) was evaluated. In the case of transferrin the mhcpe ligand is involved in the binding of V IV O 2+ to the protein, the most important species formed corresponding to (V IV O)(hTF)(mhcpe) and (V IV O) 2 (hTF)(mhcpe) 2 . Strong induced CD-signals were recorded for mhcpe-intraligand CD bands as well as ICD in d-d transitions of V IV , indicating that these V IV -mhcpe ternary species are in close interaction with chiral groups of the iron binding site of hTF; similar bands were also recorded for (V IV O) n (hTF)(maltol) m and (V IV O) n (hTF)(dhp) m ternary complexes. 57 V IV O-HSA-mhcpe species may also form and were identified by both EPR and CD spectra. However, CD spectra recorded under conditions close to those existing in human blood serum, namely with a concentration of HSA of ca. 630 μM and hTF of ca. 40 μM, up to a total vanadium concentration of 80 μM, indicate that V IV O-mhcpe species bind mainly to hTF. Similar conclusions are made in the case of maltol and dhp. For higher vanadium concentrations HSA may start being a relevant V IV O-binder.
When Fe III is present or is added to solutions containing hTF, V IV O 2+ and mhcpe, the Fe III binds hTF removing an equivalent number of V IV O-complexes, and EPR spectra clearly show both the signals of Fe III -hTF and of V IV O-hTF species. However, in the presence of Fe III the EPR and CD spectroscopic signals due to V IV O disappear much faster than in its absence, and a significant amount of V V -hTF species is detected by 51 V NMR in the obtained solutions.
In conclusion, the newly synthesized compound mhcpe is a suitable carrier ligand for V IV O, being able to engage the metal ion in stable complexes and assisting its transport in blood plasma conditions through transferrin binding with the formation of ternary species involving the V IV O metal ion, mhcpe and transferrin. Binding to mhcpe does not modify the preference of V IV O 2+ for transferrin despite the major concentration of albumin available in blood plasma conditions. These interactions may be of relevance for the cellular uptake of V IV O mediated by the transferrin receptor.
Experimental section
Synthesis Synthesis of benzyl benzyloxyacetate. 80 A suspension of sodium hydride (1.18 g, 60% in oil, 30 mmol) in dry THF (20 mL) was added to benzyl alcohol (3 g, 30 mmol) at 0°C. Benzyl bromoacetate (6.9 g, 30 mmol) was added dropwise. After being stirred for 24 hours, the reaction mixture was poured into water and extracted twice with ether. The combined organic extracts were dried over anhydrous Na 2 SO 4 / H 2 SO 4 (conc.). Purification on a silica gel column (hexaneethyl acetate 6 : 1) yielded the title compound as an oil. Yield: 76%. 1 , and ethanol (0.2 mL) were dissolved in dry THF (100 mL). NaH (2.34 g, 60% in oil, 58.5 mmol) was added and the mixture was stirred at room temperature for 48 h. THF was removed under vacuum, and the residue was dissolved in ethanol (100 mL), followed by addition of sodium ethoxide (3.75 g, 55.1 mmol) and acetamidine hydrochloride (5.21 g, 5.11 mmol). After stirring at 60°C for 14 h, the resulting suspension was cooled to room temperature, and most of the solvent removed under vacuum. The resulting oil was extracted with CH 2 Cl 2 and H 2 O. The pH of the aqueous phase was adjusted to ∼6 with HCl (conc.) and both phases were washed several times. The organic phase was separated, dried with anhydrous Na 2 SO 4 and the CH 2 Cl 2 evaporated till an orange oil was obtained. This was immediately shaken with diethyl ether (30 mL) and left in the freezer. A white solid precipitated, filtered, and 4.3 g of 2-methyl-3H-5-benzyloxy-6carboxy-4-pyrimidinone ethyl ester were obtained. The residual oil was separated by chromatography (silica gel) with a mixture of ethyl acetate and CH 2 Cl 2 (1 : 1) and 2.1 g 2-methyl-3H-5-benzyloxy-6-carboxy-4-pyrimidinone ethyl ester were additionally obtained. Yield: 40.5%. M.p.: 125-126°C. Elemental analysis: found (calc. for C 15 Synthesis of 2-methyl-3H-5-hydroxy-6-carboxy-4-pyrimidinone ethyl ester (1, mhcpe). The 2-methyl-3H-5-benzyloxy-6carboxy-4-pyrimidinone ethyl ester (0.600 g, 2.08 mmol) was dissolved in acetic acid (20 mL) and Pd/C 5% (30 mg) was added to the solution. This mixture was stirred vigorously under a H 2 atmosphere for 8 h at room temperature. After Pd/C filtration, a precipitate was obtained from the solution by partial evaporation of the solvent. This precipitate was dissolved in methanol. The white solid obtained from this methanolic solution is mhcpe, 1, (0.22 g; yield: 53.4%). Crystals from the solution suitable for X-ray diffraction were obtained. Synthesis of 2,3-dimethyl 5-benzyloxy-6-carboxy-4-pyrimidinone ethyl ester (2, dbcpe) . A solution of 1 (4.88 g, 16.9 mmol) in DMF (20 mL) was added dropwise to a stirred suspension of NaH (0.745 g, 60% in oil, 18.6 mmol) in dry DMF (20 mL) over ∼20 min maintaining gentle effervescence. After H 2 evolution had ceased, methyl iodide (1.27 mL, 20.4 mmol) was added in one portion and the reaction mixture was stirred at room temperature during 4 h. The excess hydride was quenched with ethanol (2 mL), and DMF was removed by rotary evaporation under vacuum. Addition of water produced an oily 'solid' which became an off-white crystalline mass upon further shaking. This solid was separated by filtration, dried briefly, and then washed with hexane (3 × 20 mL) to afford 3.0 g (∼10 mmol) of crude 2,3-dimethyl-5-benzyloxy-6-carboxy-4-pyrimidinone ethyl ester (2, dbcpe) . This crude product was recrystallized in chloroform and crystals of dbcpe suitable for X-ray diffraction were obtained. Yield: 58.8%. 1 Synthesis of N-methyl-2,3-dimethyl-5-benzyloxy-6-carboxyamido-4-pyrimidinone. Carbonyl diimidazole (0.625 g, 3.86 mmol) was added in several portions during 10 min to a slurry of HOPY acid (4, 1 g, 3.63 mmol) in CH 2 Cl 2 (10 mL). After a further 5 min period, methylamine (0.113 g, 1.82 mL of 2 M THF solution, 3.63 mmol) mixed with 5 mL of CH 2 Cl 2 was added dropwise during 5 min, and the reaction mixture was stirred for 12 h. The CH 2 Cl 2 was removed and the resultant oil shaken with ethanol-diethyl ether (1 : 10). The white precipitate obtained was filtered and washed with diethyl ether. Yield, 51.8%. Elemental analysis: found (calc. for C 15 Synthesis of N-methyl-2,3-dimethyl-5-hydroxy-6-carboxyamido-4-pyrimidinone (N-MeHOPY, 3). N-Methyl-2,3-dimethyl-5-benzyloxy-6-carboxyamido-4-pyrimidinone (0.500 g, 1.74 mmol) was dissolved in acetic acid (20 mL) and Pd/C 5% (30 mg) was added to the solution. This mixture was stirred vigorously under a H 2 atmosphere for 4 h at room temperature. After Pd/C filtration, an oil was obtained from the solution by partial evaporation of the solvent and was precipitated with hexane. A white precipitate of N-MeHOPY (3) was isolated by filtration and was washed with hexane. Crystals of N-MeHOPY suitable for X-ray diffraction were grown in acetic acid-hexane Determination of protonation and formation constants of mhcpe and V IV O-mhcpe systems pH-potentiometric titrations. All measurements were made in aqueous solution. The purity of the ligand was checked pHpotentiometrically and the exact concentrations of solutions were determined by checking the inflection points of the titrations by the Gran method. Two stock solutions of V IV O(ClO 4 ) 2 were used and their V IV O 2+ and H 3 O + concentrations were determined and standardized as reported earlier 62, 81 by pHpotentiometry. The V IV O 2+ concentrations were ca. 300 mM and ca. 180 mM and dilutions were made as appropriate. The V V stock solution (∼30 mM) was prepared by dissolving KVO 3 (Sigma-Aldrich) in an accurately measured volume of a KOH solution of known molarity (0.2034 M), and its OH − concentration was calculated taking into account the total volume of the vanadate stock solution prepared.
All solutions were manipulated in an inert atmosphere (high purity N 2 ). The ionic strength was adjusted to 0.20 M KCl and the temperature was 25.0 ± 0.1°C. The pH was measured with a Thermo Orion 420A+ pH-meter with a Mettler Toledo U402-M3-S7/200 combined electrode, calibrated for hydrogen ion concentration as described earlier. 62 The ionic product of water was pK w = 13.72.
Determination of protonation constants. For the determination of the protonation constants several sets of UV absorption spectra (210-380 nm) with concentrations of ca. 10 −4 M were measured in the pH range ca. 0.5 to 12, and five pH titration curves were also measured in the pH range ca. 1.8 to 12. An individual calibration curve EMF vs. [H + ] was established for pH values < ∼2, valid for the present medium and electrodes. For this purpose a set of HCl solutions were prepared with known H + concentration, from pH ca. 0.8 to 2.0, all with an ionic strength of 0.20 M. The protonation constant β 2 of mhcpe was determined from the five titration curves of 10 to 15 mL samples, with initial concentrations in the range 0.0032 to 0.012 M, using the SUPERQUAD computer program. 82 Both protonation constants β 1 and β 2 of MHCPE were determined from the UV spectra in the pH range 0.8 to 8 using the PSEQUAD computer program. 59 The calculated pK a values determined from the UV spectra were pK a1 = 1.14 and pK a2 = 6.34. The pK a2 calculated from the pH-metric titration is 6.36.
Determination of formation constants. For the determination of the stability constants of the V IV O-mhcpe system several sets of visible absorption spectra (350-900 nm) were measured in the pH range ca. 0. The hydrolytic constants of V IV O 2+ , the protonation constants of mhcpe − , all formation constants of V IV O-mhcpe complexes (see above) and the conditional stability constants for the binary species (V IV O)-hTF and (V IV O) 2 -hTF 40 were taken into account in the calculations for the V IV O-apo-hTF-mhcpe system with the PSEQUAD computer program.
Spectroscopic measurements
Physical and spectroscopic studies. IR spectra were recorded either with a BioRad FTS 3000 MX FTIR or with a Jasco FTIR 430 spectrometer. The CD spectra were recorded with a JASCO 720 spectropolarimeter, either with a red-sensitive photomultiplier (EXEL-308) suitable for the 400-1000 nm range or with the photomultiplier suitable for the 170-700 nm range. Visible spectra were recorded with a Hitachi U-2000 spectrophotometer. The EPR spectra were recorded at 77 K (on glasses made by freezing solutions in liquid nitrogen) with a Bruker ESP 300E X-band spectrometer. The 1 H NMR and 51 V NMR spectra were obtained on a Bruker Avance III 400 MHz spectrometer at ca. 25°C.
UV-Vis spectroscopy. All measurements with the mhcpe solutions were made in water at I = 0.20 M KCl (for pH < 2 KCl-HCl mixtures with I = 0.2 M were used, see below). The temperature was kept at 25.0 ± 0.3°C with circulating water. Unless otherwise stated, by visible (Vis) spectra we mean a representation of ε m vs. λ [ε m = absorption/(bC M ), where b = optical path and C M = total V IV concentration]. The spectral range covered was normally 210-390 nm (UV) or 350-900 nm (Vis), with a 10 mm optical path quartz cell. Normally, but not in all cases, the spectra were recorded changing the pH with approximately fixed total vanadium and ligand concentrations.
Circular dichroism. All measurements were made in water and the temperature was kept at ca. 25.0 ± 1°C. Unless otherwise stated, by circular dichroism (CD) spectra we mean a representation of Δε values vs. λ [Δε: differential absorption/ (bC P ) and C P = total protein concentration]. The spectral range covered was either 190-250 nm (1 mm optical path) or 250-400 nm (2 or 10 mm optical path) or 400-1000 nm (10 or 50 mm optical path, section ESI-4 †). All measurements and operations of the spectropolarimeter were computer-controlled, and the sample compartment was continuously flushed with nitrogen gas.
EPR spectroscopy. In the absence of ethylene glycol or DMSO a relatively broad background was present in most of the frozen solution EPR spectra, therefore most spectra of solutions containing V IV O 2+ and mhcpe were run with aqueous solutions containing 5% DMSO to promote the formation of a good glass.
Several sets of EPR spectra were measured for the V IV Omhcpe system in the pH range ca. 0. The EPR spectra help to elucidate which groups coordinate in solution. For the V IV O-systems we used the additivity rule to estimate the hyperfine coupling constant A z est (see above). To calculate the relevant spin-Hamiltonian parameters from the experimental EPR spectra, these were either simulated using a program from Rockenbauer and Korecz, 63 or an iterative procedure developed by Chasteen et al. 66 using the corrected equations of Casella et al. 83 aqueous buffers at pH 4.0 and 7.0). The final values of pD were determined from pD = pH* + 0.40, where pH* corresponds to the reading of the pH meter. For the acquisition of 1 H NMR spectra to access protonation steps of mhcpe a ∼5 mM solution of mhcpe was prepared at pD ∼ 10 in D 2 O, by addition of CO 2 -free NaOD. The measurements were done down to pH 1 by addition of DCl (or NaOD, whenever necessary).
The 1 H and 51 V NMR chemical shifts were referenced relative to DSS (sodium 3-trimethyl-silyl-d 4 -propionate) at 0 ppm and to external neat VOCl 3 at 0 ppm, respectively. 51 V NMR acquisition parameters were: 33 kHz spectral width, 30 μs pulse width, 1 s acquisition time and 10 Hz line broadening. The signal intensities of the NMR resonances were obtained using the line-fitting routine supplied with the NUTS™ PCbased NMR spectral analysis program.
Preparation of solutions containing vanadium, apotransferrin, mhcpe and iron
Most samples containing V IV O were manipulated in a glove bag purged with nitrogen or argon gas.
Hepes-S buffer. The composition of the Hepes-S buffer used is 50 mM Hepes (Sigma-Aldrich), 25 mM carbonate added as NaHCO 3 (Sigma-Aldrich), 1 mM phosphate added as NaH 2 PO 4 ·H 2 O (Merck) and 0.20 mM KCl (Merck). This buffer system was adjusted to a pH of 7.4 using conc. KOH.
Hepes-CL buffer. The composition of the Hepes-CL buffer used is similar to that of Hepes-S, but additionally it also contains: 0.1 mM citrate and 1.5 mM lactate. This buffer system was also adjusted to pH 7.4 using conc. KOH. No clearly measurable CD spectrum in the visible range (400-1000 nm) is obtained with solutions of V IV OSO 4 and mhcpe (1 : 1) in this buffer; thus no ternary V IV O-lactate-mhcpe or V IV O-citratemhcpe complexes can be detected by CD under these conditions. PBS buffer. Phosphate buffered saline (PBS) from Sigma-Aldrich was used. One tablet dissolved in 200 mL of Milli-pore® water yields 0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4, at 25°C. Every PBS solution used in this work also contains 25 mM NaHCO 3 .
V IV O-solutions. For all experiments involving studies with solutions containing serum proteins, a stock V IV O(SO 4 ) solution was used (99.0 mM, pH ∼ 2), which was first diluted as appropriate (e.g. to 9.90 mM or 0.990 mM), and then used in the experiments.
Protein solutions. Human apo-transferrin solutions were prepared by dissolving the protein, either transferrin (Sigma, T4382) or human serum albumin (Sigma, A1653, fatted) in buffer at pH 7.4. The solutions were allowed to stand for at least 1 h to allow equilibration. During this period they were gently swirled without strong agitation. The concentrations of the protein solutions were determined by measuring the absorbance at 280 nm using an extinction coefficient of 92 300 M −1 cm −1 for apo-transferrin, 40, 84, 85 and 36 850 M −1 cm −1 for HSA. 86, 87 Normally argon was bubbled through all solutions prior to use for measurements with V IV -complexes to displace any oxygen that may be present, and the solutions were kept and manipulated under an argon atmosphere inside a glove bag.
Iron transferrin solutions were prepared by dissolving the ferrous ammonium sulfate hexahydrate salt (Fe(NH 4 ) 2 -(SO 4 ) 2 ·6H 2 O, Mohr's salt) in the apo-hTF solution in buffer. The solution of Fe-hTF was kept for ca. 24 h so that Fe III forms and binds to hTF yielding the Fe III -hTF complex. For (Fe) 2 -hTF an extinction coefficient of 113 000 M −1 cm −1 was used. 51 Loading of Fe III onto hTF. Samples containing Fe III were prepared from stock solutions of Mohr's salt ((NH 4 ) 2 Fe-(SO 4 ) 2 ·6H 2 O). Normally to form holo-transferrin (orange solution), to saturate apo-transferrin with iron, apo-transferrin solutions (colourless solution) were mixed with ferrous ammonium sulfate hexahydrate in Hepes-S or Hepes-CL buffer pH 7.4. The Fe II , from the stock solution, is then rapidly oxidized to Fe III in the presence of the protein and after degassing the solution. FeCl 3 (Merck) was used in some cases to prepare solutions that were added to solutions containing apo-hTF and/or V IV OSO 4 .
Several sets of CD (visible range) and EPR spectra were measured for the V IV O-apo-hTF-mhcpe system, normally with a transferrin concentration of 750 μM and varying the V IV Oand mhcpe-concentration. 750 μM was an adequate V IV O concentration (and thus hTF concentration for 1 : 1 ratios) to produce EPR spectra suitable for simulation. Most of these spectra were measured with buffer solutions at pH = 7.4. Most preparations were done under argon doing all manipulations inside glove bags. The CD spectra were run either with 10 mm or 50 mm optical path quartz cells (see ESI-4 †) in the wavelength range 400-1000 nm, and the sample compartment was continuously flushed with nitrogen gas. Several CD spectra were measured with human serum albumin (ca. 0.63 mM, the HSA blood plasma concentration) varying the V IV O-and mhcpe-concentration.
Several sets of CD spectra (UV range) were measured for the V IV O-apo-hTF-mhcpe system, normally with a apo-transferrin concentration of 100 μM and varying the V IV O-and mhcpeconcentration, either using a 2 mm or a 10 mm optical path quartz cells in the wavelength range 250-400 nm.
A few CD spectra (far-UV range) were measured for the V IV O-apo-hTF, V IV O-albumin and V IV O-albumin-mhcpe systems, normally with a protein concentration of ca. 5-10 μM and varying the V IV O or the V IV O-mhcpe concentration (section ESI-9 †), using a 1 mm optical path quartz cell in the wavelength range 190-250 nm.
Several sets of CD spectra (UV range) were measured for the V IV O-apo-hTF-HSA-mhcpe system, with an albumin concentration of 630 μM and a transferrin concentration of 40 μM and varying the V IV O-and mhcpe-concentration. These spectra were measured with Hepes-S buffer solutions at pH = 7.4 and the preparations were done under argon doing all manipulations inside glove bags. The CD spectra were run with a 2 mm optical path quartz cell in the wavelength range 250-400 nm, Table 6 Crystal and structure refinement data a for mhcpe (1), dbcpe (2) and (dbcpe) and N-MeHOPY (3). 
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